Table 1.

Prognostic analysis of demographic, disease, and histological factors

Subgroup	Univariate p-value	Multivariate p-valueb
MONARCH 2 and MONARCH 3 a
Age	0.9343	N/A
Race	0.0046	N/A
ECOG PS	0.0069	0.0020
Bone-only disease	<.0001	0.0007
Visceral disease	<.0001	N/A
Liver metastases	<.0001	<.0001
Lung metastases	0.5067	N/A
Pleural metastases	0.4619	N/A
PgR status	0.0205	0.0070
Grade	0.0016	0.0017
No. of organs at baseline	0.0003	N/A
Prior neoadjuvant or adjuvant chemotherapy	0.3204	N/A
MONARCH 2 only c
Number of lines of ET	0.2944	N/A
Last Line of ET	0.6673	N/A
ET Resistance	0.1142	N/A
MONARCH 3 only c
Treatment-free interval	0.0225	N/A
Time from diagnosis to recurrence	0.0224	N/A
De novo metastatic disease	0.9266	N/A

ECOG PS Eastern Cooperative Oncology Group performance status, ET endocrine therapy, N/A not applicable, PgR progesterone receptor

^aPooled univariate and multivariate analyses were stratified by study and treatment arm

^bPatients with any missing potential baseline prognostic factors were removed from the multivariate analysis. The stepwise selection used p-value < 0.05 as the criterion for adding a variable and p-value ≥ 0.05 for dropping a variable

^cMONARCH 2 only and MONARCH 3 only were stratified by study stratification factors and treatment arm